These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 21146629)

  • 1. In vitro models for human skin disease.
    Semlin L; Schäfer-Korting M; Borelli C; Korting HC
    Drug Discov Today; 2011 Feb; 16(3-4):132-9. PubMed ID: 21146629
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro skin irritation: facts and future. State of the art review of mechanisms and models.
    Welss T; Basketter DA; Schröder KR
    Toxicol In Vitro; 2004 Jun; 18(3):231-43. PubMed ID: 15046769
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reconstructed skin equivalents for assessing percutaneous drug absorption from pharmaceutical formulations.
    Zghoul N; Fuchs R; Lehr CM; Schaefer UF
    ALTEX; 2001; 18(2):103-6. PubMed ID: 11378682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of genotoxicity test procedures with Episkin, a reconstructed human skin model: towards new tools for in vitro risk assessment of dermally applied compounds?
    Flamand N; Marrot L; Belaidi JP; Bourouf L; Dourille E; Feltes M; Meunier JR
    Mutat Res; 2006 Jul; 606(1-2):39-51. PubMed ID: 16675293
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [3D cellular models: a powerful access to cutaneous physiology and to innovative developments of cosmetic active compounds].
    André V; Grenier S; Pivard F; Perrier E
    Pathol Biol (Paris); 2005 Dec; 53(10):618-26. PubMed ID: 16364814
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use of skin models in drug development.
    Mathes SH; Ruffner H; Graf-Hausner U
    Adv Drug Deliv Rev; 2014 Apr; 69-70():81-102. PubMed ID: 24378581
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative analysis of solar radiation-induced cellular damage between ex vivo porcine skin organ culture and in vitro reconstructed human epidermis.
    Bacqueville D; Mavon A
    Int J Cosmet Sci; 2009 Aug; 31(4):293-302. PubMed ID: 19467030
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amended final report on the safety assessment of glyceryl dilaurate, glyceryl diarachidate, glyceryl dibehenate, glyceryl dierucate, glyceryl dihydroxystearate, glyceryl diisopalmitate, glyceryl diisostearate, glyceryl dilinoleate, glyceryl dimyristate, glyceryl dioleate, glyceryl diricinoleate, glyceryl dipalmitate, glyceryl dipalmitoleate, glyceryl distearate, glyceryl palmitate lactate, glyceryl stearate citrate, glyceryl stearate lactate, and glyceryl stearate succinate.
    Int J Toxicol; 2007; 26 Suppl 3():1-30. PubMed ID: 18273450
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro irritation models and immune reactions.
    Gibbs S
    Skin Pharmacol Physiol; 2009; 22(2):103-13. PubMed ID: 19188758
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A tiered approach to the use of alternatives to animal testing for the safety assessment of cosmetics: skin irritation.
    Macfarlane M; Jones P; Goebel C; Dufour E; Rowland J; Araki D; Costabel-Farkas M; Hewitt NJ; Hibatallah J; Kirst A; McNamee P; Schellauf F; Scheel J
    Regul Toxicol Pharmacol; 2009 Jul; 54(2):188-96. PubMed ID: 19393278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Phenion full-thickness skin model for percutaneous absorption testing.
    Ackermann K; Borgia SL; Korting HC; Mewes KR; Schäfer-Korting M
    Skin Pharmacol Physiol; 2010; 23(2):105-12. PubMed ID: 20016252
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Three Rs potential in the development and quality control of pharmaceuticals.
    Hartung T
    ALTEX; 2001; 18 Suppl 1():3-13. PubMed ID: 11854852
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors to consider in the use of stem cells for pharmaceutic drug development and for chemical safety assessment.
    Trosko JE; Chang CC
    Toxicology; 2010 Mar; 270(1):18-34. PubMed ID: 19948204
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of human nasal in vitro cell systems during drug discovery and development.
    Dimova S; Brewster ME; Noppe M; Jorissen M; Augustijns P
    Toxicol In Vitro; 2005 Feb; 19(1):107-22. PubMed ID: 15582362
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanistic applicability domain classification of a local lymph node assay dataset for skin sensitization.
    Roberts DW; Patlewicz G; Kern PS; Gerberick F; Kimber I; Dearman RJ; Ryan CA; Basketter DA; Aptula AO
    Chem Res Toxicol; 2007 Jul; 20(7):1019-30. PubMed ID: 17555332
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Further development of the EpiDerm 3D reconstructed human skin micronucleus (RSMN) assay.
    Mun GC; Aardema MJ; Hu T; Barnett B; Kaluzhny Y; Klausner M; Karetsky V; Dahl EL; Curren RD
    Mutat Res; 2009 Mar; 673(2):92-9. PubMed ID: 19167515
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Final report on the safety assessment of capsicum annuum extract, capsicum annuum fruit extract, capsicum annuum resin, capsicum annuum fruit powder, capsicum frutescens fruit, capsicum frutescens fruit extract, capsicum frutescens resin, and capsaicin.
    Int J Toxicol; 2007; 26 Suppl 1():3-106. PubMed ID: 17365137
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amended final report on the safety assessment of Oryza Sativa (rice) Bran Oil, Oryza Sativa (rice) Germ Oil, Rice Bran Acid,Oryza Sativa (rice) Bran Wax, Hydrogenated Rice Bran Wax, Oryza Sativa (rice)Bran Extract, Oryza Sativa (rice) Extract, Oryza Sativa (rice) Germ Powder, Oryza Sativa (rice) Starch, Oryza Sativa (rice) Bran, Hydrolyzed Rice Bran Extract, Hydrolyzed Rice Bran Protein, Hydrolyzed Rice Extract, and Hydrolyzed Rice Protein.
    Int J Toxicol; 2006; 25 Suppl 2():91-120. PubMed ID: 17090480
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined effects of iontophoretic and chemical enhancement on drug delivery. II. Transport across human and murine skin.
    Nolan LM; Corish J; Corrigan OI; Fitzpatrick D
    Int J Pharm; 2007 Aug; 341(1-2):114-24. PubMed ID: 17502130
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CIRD symposium: Advances in skin pharmacology VI: Toxicity after topical application. 4-6 October 1985, Sophia Antipolis, France.
    Br J Dermatol; 1986 Aug; 115 Suppl 31():1-149. PubMed ID: 3741791
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.